The mission of the Comprehensive Cancer Center at St. Jude Children's Research Hospital (SJCCC) is to advance cures and means of prevention for pediatric cancer: the leading cause of disease-related death in children aged 1 to 14 years. For 36 of our 50 year history, we have pursued this mission with the support of a Cancer Center Support Grant from the National Cancer Institute (NCI). We remain the only NCI designated Cancer Center that is dedicated solely to the research and treatment of pediatric malignancies. As such, we serve as a national and international resource for health care providers, children with cancer, and their families. Through the support of the American Lebanese and Syrian Associated Charities (ALSAC), a separate corporation whose sole purpose is to raise money in support of St. Jude Children's Research Hospital (SJCRH), patients are accepted without regard to race, religion or ability to pay. Seventy-five percent of the total institutional space and annul budget are invested in the SJCCC. The current application proposes five multidisciplinary research Programs that are organized with the specific intent of translating basic science discoveries into curative therapies for children with cancer, while minimizing long-term side effects: our three disease-oriented Programs focus on Developmental Biology and Solid Tumors (DBSTP), Hematological Malignancies (HMP), and Neurobiology and Brain Tumors (NBTP);our Cancer Prevention and Control Program (CPCP) strives to improve the quality of life of individuals surviving childhood cancer;and our new Cancer Genetics, Biochemistry and Cell Biology Program (CGBCBP), formed by merging our two prior basic laboratory research Programs, embeds basic cancer research within the heart of the SJCCC, facilitating direct interaction between the disease-oriented Programs and the major laboratory resources in the Center. Research by the 144 aligned members is supported by 10 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Director was appointed and several enhancements were made to the overall structure, policies, and procedures of the SJCCC. 32,522 clinical trial enrollments occurred at the Center during the current funding period, of which 56% were to SJCCC investigator initiated studies. External peer reviewed trials, many which are SJCCC member-led, accounted for another 38% of enrollments. SJCCC members published more than 2,100 manuscripts during the funding period, and in the last 12 months were supported by $69.4 million in extramural funding ($57 million, peer-reviewed;$12.4 million, non-peer-reviewed). The five multidisciplinary research Programs and ten Shared Resources in the SJCCC work together to find cures for pediatric cancer, while minimizing the long-term side effects of treatment. With strong institutional and philanthropic support, for 50 years we have served as a national and international resource for health care providers, children with cancer, and their families. In this mission we accept patients without regard to race, religion or ability to pay.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-35S1
Application #
8928734
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-04-01
Project End
2019-02-28
Budget Start
2014-06-09
Budget End
2015-02-28
Support Year
35
Fiscal Year
2014
Total Cost
$75,000
Indirect Cost
$32,627
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Stewart, Daniel P; Marada, Suresh; Bodeen, William J et al. (2018) Cleavage activates dispatched for Sonic Hedgehog ligand release. Elife 7:
Vo, BaoHan T; Kwon, Jin Ah; Li, Chunliang et al. (2018) Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733
Ehrhardt, Matthew J; Mulrooney, Daniel A; Li, Chenghong et al. (2018) Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma. Cancer 124:417-425
Ramsey, Laura B; Balis, Frank M; O'Brien, Maureen M et al. (2018) Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 23:52-61
Ma, Xiaotu; Liu, Yu; Liu, Yanling et al. (2018) Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555:371-376
Huang, I-Chan; Klosky, James L; Young, Chelsea M et al. (2018) Misclassification of self-reported smoking in adult survivors of childhood cancer. Pediatr Blood Cancer 65:e27240
Watson, Edmond R; Brown, Nicholas G; Peters, Jan-Michael et al. (2018) Posing the APC/C E3 Ubiquitin Ligase to Orchestrate Cell Division. Trends Cell Biol :
Drummond, Catherine J; Hanna, Jason A; Garcia, Matthew R et al. (2018) Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. Cancer Cell 33:108-124.e5
Inskip, Peter D; Veiga, Lene H S; Brenner, Alina V et al. (2018) Hypothyroidism after Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Radiat Res 190:117-132
Diouf, Barthelemy; Lin, Wenwei; Goktug, Asli et al. (2018) Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discov 23:164-173

Showing the most recent 10 out of 6764 publications